Precision radiation may boost second stem cell transplants for relapsed blood cancers

NCT ID NCT02333162

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the cancer from coming back. The study involves 30 participants and is currently on hold.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Fludarabine phosphate, melphalan, and intensity-modulated total marrow irradiation (IMTMI)
What this could lead to
If it works, this could lead to a safer way to prepare the body for a second stem cell transplant, potentially reducing relapse and side effects for people with advanced blood cancers.
What could go wrong
This is a very early (Phase I) and small trial (30 people) that is currently suspended. It focuses on safety and dosing, not yet on effectiveness. There are significant risks from the chemotherapy, radiation, and transplant itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNANCY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Chicago Comprehensive Cancer Center

    Chicago, Illinois, 60637, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.